The former CEO of the collagen company is now leading Supergut, which plays in an emerging but competitive category of ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...